Wesslén L - Search Results

1

Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.

Kileng H, Kjellin M, Akaberi D, Bergfors A, Duberg AS, Wesslén L, Danielsson A, Gangsøy Kristiansen M, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Kileng H, et al. Among authors: wesslen l. Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1347-1353. doi: 10.1080/00365521.2018.1511824. Epub 2018 Nov 5. Scand J Gastroenterol. 2018. PMID: 30394152

2

Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.

Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, Duberg AS, Lennerstrand J. Palanisamy N, et al. Among authors: wesslen l. Antiviral Res. 2013 Jul;99(1):12-7. doi: 10.1016/j.antiviral.2013.04.018. Epub 2013 May 3. Antiviral Res. 2013. PMID: 23648709

3

Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.

Lindström I, Kjellin M, Palanisamy N, Bondeson K, Wesslén L, Lannergard A, Lennerstrand J. Lindström I, et al. Among authors: wesslen l. Infect Dis (Lond). 2015 Aug;47(8):555-62. doi: 10.3109/23744235.2015.1028097. Epub 2015 Apr 8. Infect Dis (Lond). 2015. PMID: 25851241

4

Immune function in Swedish élite orienteers.

Lannergård A, Fohlman J, Wesslén L, Rolf C, Friman G. Lannergård A, et al. Among authors: wesslen l. Scand J Med Sci Sports. 2001 Oct;11(5):274-9. doi: 10.1034/j.1600-0838.2001.110504.x. Scand J Med Sci Sports. 2001. PMID: 11696211

5

Bartonella spp. seroprevalence in healthy Swedish blood donors.

McGill S, Wesslén L, Hjelm E, Holmberg M, Auvinen MK, Berggren K, Grandin-Jarl B, Johnson U, Wikström S, Friman G. McGill S, et al. Among authors: wesslen l. Scand J Infect Dis. 2005;37(10):723-30. doi: 10.1080/00365540510012152. Scand J Infect Dis. 2005. PMID: 16191889

6

Genotypic and serotypic profile in dilated cardiomyopathy.

Wesslén L, Waldenström A, Lindblom B, Høyer S, Friman G, Fohlman J. Wesslén L, et al. Scand J Infect Dis Suppl. 1993;88:87-91. Scand J Infect Dis Suppl. 1993. PMID: 8390721

7

Antibodies to Chlamydia pneumoniae in young Swedish orienteers.

Hjelm E, Wesslén L, Gnarpe H, Gnarpe J, Nyström-Rosander C, Rolf C, Friman G. Hjelm E, et al. Among authors: wesslen l. Scand J Infect Dis. 2001;33(8):589-92. doi: 10.1080/00365540110026674. Scand J Infect Dis. 2001. PMID: 11525352

8

Serological and epidemiological analysis of the prevalence of Bartonella spp. antibodies in Swedish elite orienteers 1992-93.

McGill S, Wesslen L, Hjelm E, Holmberg M, Rolf C, Friman G. McGill S, et al. Among authors: wesslen l. Scand J Infect Dis. 2001;33(6):423-8. doi: 10.1080/00365540152029882. Scand J Infect Dis. 2001. PMID: 11450861

9

Infectious and lymphocytic myocarditis: epidemiology and factors relevant to sports medicine.

Friman G, Wesslén L, Karjalainen J, Rolf C. Friman G, et al. Among authors: wesslen l. Scand J Med Sci Sports. 1995 Oct;5(5):269-78. doi: 10.1111/j.1600-0838.1995.tb00044.x. Scand J Med Sci Sports. 1995. PMID: 8581569 Review.

10

The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy.

Friman G, Wesslén L, Fohlman J, Karjalainen J, Rolf C. Friman G, et al. Among authors: wesslen l. Eur Heart J. 1995 Dec;16 Suppl O:36-41. doi: 10.1093/eurheartj/16.suppl_o.36. Eur Heart J. 1995. PMID: 8682098 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page